We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Value of <sup>111</sup>In-DOTA-lanreotide and <sup>111</sup>In-DOTA- DPhe<sup>1</sup>-Tyr<sup>3</sup>-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with <sup>18</sup>F-FDG PET.
- Authors
Rodrigues, Margarida; Traub-Weidinger, Tatjana; Leimer, Maria; Li, Shuren; Andreae, Fritz; Angelberger, Peter; Dudczak, Robert; Virgolini, Irene
- Abstract
Purpose: Radioiodine-negative thyroid cancer presents diagnostic and therapeutic difficulties, warranting the implementation of new imaging and treatment strategies. The purpose of this study was twofold. First, we investigated in vitro the binding characteristics of 111In-DOTA-lanreotide (111In-DOTA-LAN) and 111In-DOTA-DPhe¹-Tyr³-octreotide (111In-DOTA-TOC) to cells derived from differentiated thyroid cancer (DTC). Second, we evaluated the value of somatostatin receptor (SSTR) scintigraphy with these radioligands, as compared with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), for the detection of tumour lesions in DTC patients. Methods: Binding of 111In-DOTA-LAN and 111In-DOTATOC to cells isolated from surgically removed thyroid tissue was evaluated in vitro by performing saturation and displacement studies. Eighteen DTC patients with elevated thyroglobulin (12 radioiodine-negative, six radioiodine-positive) were investigated with 111In-DOTA-LAN, 111In-DOTA-TOC and 18F-FDG PET scans. Results: Large numbers of SSTR binding sites for 111In-DOTA-LAN and 111In-DOTA-TOC were found on the cells investigated. Both SSTR radioligands exhibited a high binding affinity for these SSTR binding sites. 111In-DOTALAN and 111In-DOTA-TOC scintigraphy detected 37 and 33 lesions, respectively, in 17 (94%) patients each, whereas 18F-FDG PET revealed 30 lesions in 15 (83%) patients. Uptake of both SSTR radioligands was found in several radioiodine-negative sites. No striking differences in lesion imaging by 111In-DOTA-LAN and 111In-DOTA-TOC were found. In both radioiodine-negative and radioiodine-positive patients, more lesions were SSTR-positive/18F-FDG-negative than were 18F-FDG-positive/SSTR-negative. Conclusion: Adding a SSTR scan with these radioligands to the diagnostic work-up increases the diagnostic capacity in DTC, and should be considered particularly in radioiodine-negative patients with elevated thyroglobulin levels.
- Subjects
THYROID cancer; IODINE isotopes; DIAGNOSIS; THERAPEUTICS; POSITRON emission tomography; DIAGNOSTIC imaging; TUMORS; NUCLEAR medicine
- Publication
European Journal of Nuclear Medicine & Molecular Imaging, 2005, Vol 32, Issue 10, p1144
- ISSN
1619-7070
- Publication type
Article
- DOI
10.1007/s00259-005-1820-1